Three IPOs and one SPAC priced this week, while two IPOs and five SPACs submitted filings. China-based Londian Wason New Energy Tech (FOIL) priced its upsized US IPO at the top of the range to raise $94 million at a market cap of $1.7 billion ($3.1 billion...read more
Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, raised $81 million by offering 6.3 million shares at $13, the high end of the $11 to $13 range. VogenX is a clinical-stage biopharmaceutical company developing therapies...read more
Updated Monday, 8/3. Six IPOs are currently scheduled for the week ahead, featuring five biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up...read more
Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, announced terms for its IPO on Wednesday. The Raleigh, NC-based company plans to raise $75 million by offering 6.3 million shares at a price range of $11 to $13. At the...read more
US IPO Weekly Recap: Copper foils producer and metabolic disorders biotech list amid August lull
Three IPOs and one SPAC priced this week, while two IPOs and five SPACs submitted filings. China-based Londian Wason New Energy Tech (FOIL) priced its upsized US IPO at the top of the range to raise $94 million at a market cap of $1.7 billion ($3.1 billion...read more
Metabolic disorders biotech Vogenx prices IPO at $13, the high end of the range
Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, raised $81 million by offering 6.3 million shares at $13, the high end of the $11 to $13 range. VogenX is a clinical-stage biopharmaceutical company developing therapies...read more
US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings
Updated Monday, 8/3. Six IPOs are currently scheduled for the week ahead, featuring five biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up...read more
Metabolic disorders biotech Vogenx sets terms for $75 million IPO
Vogenx, a Phase 2b biotech developing therapies for endocrine and metabolic disorders, announced terms for its IPO on Wednesday. The Raleigh, NC-based company plans to raise $75 million by offering 6.3 million shares at a price range of $11 to $13. At the...read more